Skin cancer incidence up after pancreas transplantation

Skin cancer incidence up after pancreas transplantation
Nonmelanoma skin cancers commonly occur after pancreas transplantation, particularly in those who have a history of skin cancer, according to a study published in the October issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Nonmelanoma skin cancers (NMSCs) commonly occur after pancreas transplantation (PT), particularly in those who have a history of skin cancer, according to a study published in the October issue of the Journal of the American Academy of Dermatology.

Joshua P. Spanogle, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues conducted a retrospective study involving 216 patients who had received allogeneic PT. Recipients were assessed at two, five, and 10 years after transplantation to evaluate the incidence, , and risk factors for skin cancer.

The researchers found that the cumulative incidence of any skin cancer was 4.7 percent at two years post-transplantation; 12.7 percent at five years; and 19.6 percent at 10 years. The cumulative incidence of squamous cell carcinoma was 2.8, 10.3, and 16.7 percent, respectively, and the cumulative incidence of basal cell carcinoma was 2.4, 7.8, and 17.4 percent, respectively. At two years, the cumulative incidence of developing a second or was 56 and 36 percent, respectively. The only predictors of skin cancer were patient age and a history of skin cancer prior to transplant.

"In light of the substantively increased risk both for primary skin cancers and for subsequent NMSCs in the PT population, preventive and mitigating measures are crucial," the authors write. "Frequent evaluation of PT recipients by a health care professional trained in evaluating skin pathology is important in lessening the effect of NMSC, which is more easily treated in the early course of the disease."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Immunosuppressant switch cuts skin cancer post-transplant

Jul 26, 2012

(HealthDay) -- In kidney-transplant patients with at least one cutaneous squamous-cell carcinoma, switching immunosuppressants (from calcineurin inhibitors to sirolimus) is associated with increased skin cancer-free ...

Recommended for you

New breast cancer imaging method promising

1 hour ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

2 hours ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

4 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

7 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments